Gordon Mikael 4
4 · HAEMONETICS CORP · Filed May 3, 2012
Insider Transaction Report
Form 4
Gordon Mikael
President, Haemonetics Europe
Transactions
- Exercise/Conversion
Common Stock
2012-05-01$55.14/sh+4,000$220,560→ 10,838 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2012-05-01$72.50/sh−4,000$290,000→ 14,980 totalExercise: $55.14From: 2009-01-22Exp: 2015-01-22→ Common Stock (4,000 underlying) - Sale
Common Stock
2012-05-01$72.50/sh−4,000$290,000→ 6,838 total
Holdings
- 19,587
Non-Qualified Stock Option (right to buy)
Exercise: $52.94From: 2010-10-27Exp: 2016-10-27→ Common Stock (19,587 underlying) - 18,940
Non-Qualified Stock Option (right to buy)
Exercise: $54.99From: 2011-10-27Exp: 2017-10-27→ Common Stock (18,940 underlying) - 17,565
Non-Qualified Stock Option (right to buy)
Exercise: $61.34From: 2012-10-25Exp: 2018-10-25→ Common Stock (17,565 underlying) - 15,247
Non-Qualified Stock Option (right to buy)
Exercise: $54.55From: 2009-10-22Exp: 2015-10-22→ Common Stock (15,247 underlying)
Footnotes (3)
- [F1]Pursuant to a 10b5-1 Plan.
- [F2]Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.
- [F3]Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.